{
    "pmcid": "11722104",
    "qa_pairs": {
        "How many mutations does the JN.1 variant have in its spike protein, and how many of these are in the RBD?": [
            "58 mutations in the spike protein, with 27 in the RBD.",
            "45 mutations in the spike protein, with 20 in the RBD.",
            "60 mutations in the spike protein, with 30 in the RBD.",
            "50 mutations in the spike protein, with 25 in the RBD."
        ],
        "What is a suggested strategy for designing nanobody binders to counteract SARS-CoV-2 variants like KP.3 and JN.1?": [
            "Target conserved regions of the spike protein that are less prone to mutation.",
            "Focus on the most mutated regions of the spike protein to ensure binding.",
            "Design nanobodies that mimic the structure of the ACE2 receptor.",
            "Develop nanobodies that enhance the immune response to the RBD."
        ],
        "What is the primary reason for the resistance of SARS-CoV-2 variants JN.1 and KP.3 to mRNA vaccine-induced antibodies?": [
            "High number of mutations in the spike protein, particularly in the RBD.",
            "Increased replication rate of the virus.",
            "Altered viral entry mechanisms that bypass antibody recognition.",
            "Enhanced viral shedding leading to higher transmission rates."
        ],
        "What potential advantage do nanobodies have over traditional antibodies in therapeutic applications against SARS-CoV-2?": [
            "Their small size and stability make them suitable for inhalation therapies.",
            "They can be easily modified to increase their binding affinity.",
            "They are less expensive to produce than traditional antibodies.",
            "They have a longer half-life in the bloodstream compared to traditional antibodies."
        ],
        "Why is cross-reactivity with other coronaviruses considered a design goal for nanobodies targeting SARS-CoV-2 variants?": [
            "To enhance the breadth of protection by leveraging conserved structural motifs.",
            "To reduce the likelihood of viral resistance developing.",
            "To increase the specificity of nanobodies for SARS-CoV-2.",
            "To ensure that nanobodies can be used in a wider range of therapeutic applications."
        ]
    }
}